HistoSonics raises $100M in financing for expansion of novel histotripsy platform
HistoSonics, the developer of a non-invasive, novel sonic beam therapy, has raised $85 million in a financing led by Johnson & Johnson Innovation, to support its anticipated commercial launch, additional clinical trials, and to expand application development of Edison, the company’s novel histotripsy therapy platform, throughout the body.